Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has ...

At longevity clinics, people are shelling out for exhaustive medical tests and treatments like plasma exchange and peptide therapy. How much does it benefit them? By Dana G. Smith Iain Tait is not ...

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic ... lentiviral vector designed to generate ...